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Recombinant tissue plasminogen activator for acute ischaemic 
stroke: an updated systematic review and meta-analysis
Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory del Zoppo, Peter Sandercock, Richard L Lindley, Geoﬀ  Cohen
Summary
Background Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated 
soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial 
adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic 
stroke in an updated systematic review and meta-analysis.
Methods We searched for randomised trials of intravenous rt-PA versus control given within 6 h of onset of acute 
ischaemic stroke up to March 30, 2012. We estimated summary odds ratios (ORs) and 95% CI in the primary analysis for 
prespeciﬁ ed outcomes within 7 days and at the ﬁ nal follow-up of all patients treated up to 6 h after stroke.
Findings In up to 12 trials (7012 patients), rt-PA given within 6 h of stroke signiﬁ cantly increased the odds of being 
alive and independent (modiﬁ ed Rankin Scale, mRS 0–2) at ﬁ nal follow-up (1611/3483 [46·3%] vs 1434/3404 [42·1%], 
OR 1·17, 95% CI 1·06–1·29; p=0·001), absolute increase of 42 (19–66) per 1000 people treated, and favourable 
outcome (mRS 0–1) absolute increase of 55 (95% CI 33–77) per 1000. The beneﬁ t of rt-PA was greatest in patients 
treated within 3 h (mRS 0–2, 365/896 [40·7%] vs 280/883 [31·7%], 1·53, 1·26–1·86, p<0·0001), absolute beneﬁ t of 
90 (46–135) per 1000 people treated, and mRS 0–1 (283/896 [31·6%] vs 202/883 [22·9%], 1·61, 1·30–1·90; p<0·0001), 
absolute beneﬁ t 87 (46–128) per 1000 treated. Numbers of deaths within 7 days were increased (250/2807 [8·9%] vs 
174/2728 [6·4%], 1·44, 1·18–1·76; p=0·0003), but by ﬁ nal follow-up the excess was no longer signiﬁ cant 
(679/3548 [19·1%] vs 640/3464 [18·5%], 1·06, 0·94–1·20; p=0·33). Symptomatic intracranial haemorrhage 
(272/3548 [7·7%] vs 63/3463 [1·8%], 3·72, 2·98–4·64; p<0·0001) accounted for most of the early excess deaths. 
Patients older than 80 years achieved similar beneﬁ t to those aged 80 years or younger, particularly when treated early.
Interpretation The evidence indicates that intravenous rt-PA increased the proportion of patients who were alive with 
favourable outcome and alive and independent at ﬁ nal follow-up. The data strengthen previous evidence to treat patients 
as early as possible after acute ischaemic stroke, although some patients might beneﬁ t up to 6 h after stroke.
Funding UK Medical Research Council, Stroke Association, University of Edinburgh, National Health Service Health 
Technology Assessment Programme, Swedish Heart-Lung Fund, AFA Insurances Stockholm (Arbetsmarknadens 
Partners Forsakringsbolag), Karolinska Institute, Marianne and Marcus Wallenberg Foundation, Research Council of 
Norway, Oslo University Hospital.
Introduction
Recombinant tissue plasminogen activator (rt-PA, 
alteplase) was licensed in North America in 1996 for 
intravenous use within 3 h of stroke in selected patients 
after the publication of the results of the trials undertaken 
by the National Institute of Neurological Disorders and 
Stroke (NINDS), Bethesda, MD, USA, in 624 patients.1 A 
restricted conditional licence for the use of rt-PA within 
3 h of ischaemic stroke was granted in Europe in 
2002 after publication of two further trials of intravenous 
rt-PA administered up to 6 h after ischaemic stroke2,3 and 
a systematic review of 3156 patients.4,5 The European 
approval allowed treat ment, within 3 h, of patients 
younger than 80 years who also met other strict criteria.
Although the licence restricted the use of rt-PA to within 
3 h, the results of the trials6 suggested that rt-PA, given as 
late as 6 h after ischaemic stroke, might reduce the 
number of patients with poor functional outcomes.4,5 In 
that context, the Third International Stroke Trial (IST-3) 
was initiated in 2000, with the aim of providing evidence 
from a randomised trial for a wide range of patients, 
including those older than 80 years, treated between 
3–6 h, and with comorbid disorders such as previous 
stroke. Meanwhile, a meta-analysis of individual patient 
data from completed trials undertaken in 2004 suggested 
that intravenous rt-PA might be of beneﬁ t up to 
4·5 h after stroke,6 with the ﬁ ndings conﬁ rmed in 2008 in 
the ECASS 3 trial of patients younger than 80 years who 
were treated between 3·0–4·5 h after stroke.7,8 Despite this 
increasing evidence from 11 trials of 3977 patients who 
were treated up to 6 h after stroke,9 substantial uncer-
tainties10 have been caused by the lack of precision in the 
overall estimates of treatment eﬀ ects for the important 
outcomes of death and functional outcome, longest time 
window for net beneﬁ t, eﬀ ect of treatment in people older 
than 80 years (only 94 patients in this age group were 
included in the completed trials), and the eﬀ ect of factors 
such as stroke severity, stroke subtype, use of antiplatelet 
drugs before stroke, and other comorbidities (eg, previous 
stroke, diabetes, or hypertension).
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Trial design Patients
Number 
of 
patients 
Method of 
randomisation
Dose Control Antithrombotic drug 
use
Age inclusion 
range 
Stroke type Exclusion 
criteria* for 
CT-deﬁ ned 
ischaemia
Time 
after 
stroke
Final 
follow-up
Follow-up 
method 
(independent)
Mori et al,13 
1992
31 Seq Pack 0·6 mg/kg (34 mg) 
or 0·9 mg/kg 
(51 mg)
Placebo Avoid for 24 h 18–80 years Carotid 
territory; ICA or 
MCA occlusion 
on angiography
Visible 
infarction
<6 h 4 weeks At clinic (not 
stated)
JTSG,14 1993 98 Seq Pack 0·6 mg/kg (34 mg) Placebo Avoid for 24 h 18–80 years Carotid 
territory; ICA or 
MCA occlusion 
on angiography
Visible 
infarction
<6 h 4 weeks At clinic (not 
stated)
Haley et al,15 
1993
27 Seq Pack 0·85 mg/kg Placebo Avoid intravenous 
heparin for several 
hours
18–80 years Any ischaemic 
stroke
None <3 h 3 months At clinic (not 
stated)
ECASS,2 1995 620 Seq Pack 1·1 mg/kg 
(maximum 100 mg)
Placebo Aspirin or intravenous 
heparin not allowed; 
subcutaneous heparin 
allowed for <24 h; 
thereafter, any 
antithrombotic 
allowed
18–80 years Carotid 
territory
Visible 
infarction 
greater than 
a third of 
MCA territory
6 h 3 months At clinic (not 
stated)
NINDS,1 
1995
624 Seq Pack 0·9 mg/kg 
(maximum 90 mg)
Placebo Avoid for 24 h 18–80 years† Any except very 
mild and very 
severe
None 3 h 3 months At clinic 
(masked 
independent 
clinician)
ECASS II,3 
1998
800 Seq Pack 0·9 mg/kg 
(maximum 90 mg)
Placebo Aspirin or intravenous 
heparin not allowed; 
subcutaneous heparin 
allowed for <24 h
18–80 years Carotid 
territory
Visible 
infarction 
greater than 
a third of 
MCA territory
6 h 3 months At clinic (not 
stated)
ATLANTIS 
A,16 2000
142 Seq Pack 0·9 mg/kg 
(maximum 90 mg)
Placebo Avoid for 24 h 18–80 years As for NINDS None 6 h 3 months At clinic 
(masked 
independent 
clinician)
ATLANTIS 
B,17,18 1999
613 Seq Pack 0·9 mg/kg 
(maximum 90 mg)
Placebo Avoid for 24 h 18–80 years As for NINDS Visible 
infarction 
greater than 
a third of 
MCA territory
Most 
within 
5 h
3 months At clinic 
(masked 
independent 
clinician)
ECASS 3,7 
2008
821 Central 
telephone or 
internet based
0·9 mg/kg 
(maximum 90 mg)
Placebo Avoid for 24 h 18–80 years As for NINDS Visible 
infarction 
greater than 
a third of 
MCA 
territory
3·0–4·5 h 3 months At clinic 
(masked 
independent 
clinician)
Wang et al,19 
2003
100 Seq Pack 0·9 mg/kg 
(maximum 90 mg)
Open 
control
Avoid for 24 h 18–80 years As for NINDS Any visible 
infarction
6 h 3 months At clinic (not 
stated)
EPITHET,20 
2008
101 Seq Pack 0·9 mg/kg 
(maximum 90 mg)
Placebo Avoid for 24 h 18–80 years† As for NINDS Visible 
infarction 
greater than 
a third of 
MCA territory
3–6 h 3 months At clinic (not 
stated)
IST-3,21 2012 3035 Central 
telephone or 
internet based
0·9 mg/kg 
(maximum 90 mg)
Placebo 
ﬁ rst 276 
patients, 
open 
control 
thereafter
Avoid for 24 h; start 
aspirin at 24 h unless 
contraindicated
≥18 years All subtypes Visible 
infarct only if 
it appears 
>6 h after 
stroke—ie, 
incompatible 
with stated 
time after 
stroke
6 h 6 months Centralised 
telephone or 
postal 
questionnaire 
(yes)
rt-PA=recombinant tissue plasminogen activator. Seq Pack=randomised by taking the next of a sequentially numbered pack of active drug or placebo. ICA=internal carotid artery. MCA=middle cerebral artery. 
*Haemorrhage and mimics were excluded in all studies. †NINDS included 69 patients and EPITHET included 25 patients older than 80 years.
Table 1: Randomised controlled trials of rt-PA in acute ischaemic stroke, design characteristics, and other key factors
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We updated the systematic review of rt-PA to assess the 
overall eﬀ ect of intravenous rt-PA when given up to 6 h 
after stroke for important early and late outcomes, and to 
address some of the previous key uncertainties.
Methods
We updated the systematic review of trials of rt-PA in 
acute ischaemic stroke, ﬁ rst published in 1992,11 updated 
periodically in the Cochrane Database of Systematic Reviews 
since then.9 We searched using multiple over lapping 
search methods up to March, 2012 (appendix). We trans-
lated non-English language publications and obtained 
additional information from principal investigators.
We included all randomised trials of rt-PA versus control 
in patients with deﬁ nite ischaemic stroke, after having 
excluded intracerebral haemorrhage and other brain 
disorders on imaging that might account for the 
symptoms. Two reviewers independently assessed study 
quality, applied the inclusion criteria, extracted the data, 
and resolved discrepancies by discussion or asking the trial 
investigators. We excluded trials that did not provide 
relevant clinical outcomes or in which the latest follow-up 
was less than 1 month after treatment. We aimed to use 
intention-to-treat data, sought additional unpub lished data 
when necessary, and veriﬁ ed the extracted data with the 
principal investigators of the trials when possible, avoiding 
double counting of data when multiple publications arose 
from the same trial.
We extracted data using a standard form for trial 
characteristics including inclusion and exclusion criteria; 
method of randomisation; latest time to treatment; rt-PA 
dose and administration; other medical treatments; 
methods and timing of follow-up assessments; and the 
demographic details of patients. We extracted data for 
the number of patients allocated rt-PA or control with 
key early or late outcomes (detailed below) including 
the numbers within prespeciﬁ ed categories of modiﬁ ed 
Rankin Scale (mRS) score, Oxford Handicap Score 
(OHS, a further mod iﬁ cation of the mRS), or equivalent 
by the end of follow-up. We treated mRS and OHS 
scale points as being equivalent and translated Barthel 
Index scores to mRS: Barthel scores greater than 
60 are equivalent to mRS 0–2 and Barthel scores greater 
than 90 are equivalent to mRS 0–1.8 We sought to extract 
data for outcomes in key subgroups deﬁ ned by delays to 
treatment (0–3 h, 3–6 h); age (up to and including 
80 years or >80 years); presence or absence of visible 
infarction on imaging; baseline stroke severity; and 
diﬀ erent anti thrombotic regimens. Tabulations of IST-3 
data were provided by the trial statistician.
See Online for appendix
Figure 1: Eﬀ ects of rt-PA on early outcomes (7 days)
Data are numbers, unless otherwise indicated. Degrees of freedom is 1. Treatment was administered up to 6 h after the stroke. rt-PA=recombinant tissue plasminogen 
activator. IST-3=Third International Stroke Trial.
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We assessed early outcomes (within 7 days) including 
death from any cause; fatal intracranial haemorrhage 
(death attributed to intracranial haemorrhage identiﬁ ed 
on scanning or at post mortem); death not attributable 
to intracranial haemorrhage; symptomatic intracranial 
haemorrhage (as deﬁ ned in individual trials, but usually 
as worsening of neurological status contemporaneous 
with the appearance of new haemorrhage on brain 
imaging that was suﬃ  cient to cause neurological deteri-
oration); and symptomatic infarct swelling (worsening of 
neurological status contemporaneous with major infarct 
swelling on imaging). We assessed outcomes at the end 
of follow-up including death between 7 days and the end 
of follow-up; total number of deaths from all causes; alive 
and favourable outcome (deﬁ ned as mRS or OHS 0–1); 
alive and independent (deﬁ ned as mRS or OHS 0–2); 
and depen dency (deﬁ ned as mRS or OHS 3–5).
Statistical analyses were all prespeciﬁ ed in the review 
protocol.9 The primary analysis was for all patients 
treated up to 6 h after stroke. We also assessed the eﬀ ect 
of rt-PA given within 3 h and between 3–6 h of the stroke, 
and in patients aged up to 80 years versus those older 
than 80 years; for analyses subdivided by time to 
treatment we have used time to randomisation in IST-3 
because this provides an unbiased estimate of time to 
treatment, which is applicable to patients allocated rt-PA 
and open control. We calculated odds ratios (ORs) and 
95% CI for each outcome, unadjusted for baseline 
variables, using standard ﬁ xed-eﬀ ects methods,12 and 
calculated statistical heterogeneity using the χ² statistic, 
mentioned when signiﬁ cant hetero geneity was present. 
We provided data for the comparison of the overall 
estimate from the 11 previous trials with IST-3 and with 
the updated overall estimate of eﬀ ect. We calculated the 
absolute eﬀ ects per 1000 patients treated. The ﬁ gures 
were prepared in R (version 2.11.1).
Role of the funding source
The sponsors and funding agencies were not involved in 
the design or execution of the review or interpretation 
of the data. No drug manufacturing company was 
involved in the study design, data collection, analysis, 
and interpretation, writing of the report, or decision to 
submit this report for publication. All authors saw and 
approved the ﬁ nal version of the report. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
12 trials of intravenous rt-PA versus control, with 
7012 patients (appendix p 4), were included in this 
systematic review and meta-analysis.1–3,7,13–21 Key meth-
odological characteristics are identiﬁ ed in table 1 and 
further details are reported elsewhere.9,21 Most data 
(5276 patients [75%]) were from trials that were done in 
Europe. We judged the risk of bias to be low across all 
trials. Most trials included patients with diﬀ erent stroke 
severities and aetiological subtypes (eg, lacunar in 
NINDS and IST-3), although the results were not 
reported by subtype in most trials. Centralised random-
isation, by telephone or through a secure web server to 
ensure allo cation concealment, was used in two trials.7,21 
The total rt-PA dose was about 0·6 mg/kg13,14 to 
1·1 mg/kg.2 An identical-looking placebo was used in all 
except two trials.19,21 Final follow-up was at 1 month in two 
trials,13,14 6 months in the IST-3 trial, and 3 months in the 
other trials. In four trials, follow-up had to be done by a 
masked clinician who was not involved in the initial care 
of the patient;1,7,16–18 mostly postal or masked telephone 
follow-up was used in IST-3; follow-up masking was not 
speciﬁ ed in the remaining trials. Functional outcomes 
were not available for two trials.14,15 All trials included 
patients who were taking aspirin before the stroke; 
Eﬀ ect per 
1000 patients 
treated (95% CI)
Heterogeneity
χ² Df p value
Events within 7 days, treatment up to 6 h after stroke
Death (total) 25 (11 to 39) 7·34 7 0·39
Fatal intracranial haemorrhage 29 (23 to 36) 6·29 7 0·51
Death (not due to intracranial haemorrhage) –4 (–16 to 8)* 5·73 4 0·22
Symptomatic intracranial haemorrhage 58 (49 to 68) 15·24 11 0·17
Symptomatic oedema –2 (–18 to 13)* 17·47 5 0·004
Events by end of follow-up, treatment up to 6 h after stroke
Deaths between 7 days and end of follow–up –22 (–39 to –4) 4·88 5 0·43
Deaths by end of follow–up 7 (–11 to 25)* 17·70 11 0·09
Alive and independent (mRS 0–2) 42 (19 to 66) 17·06 9 0·05
Alive and favourable outcome (mRS 0–1) 55 (33 to 77) 21·12 9 0·01
Dependent (mRS 3–5) –50 (–73 to –27)* 19·08 9 0·02
Outcome by time to treatment
Alive, favourable outcome (mRS 0–1), <3 h 87 (46 to 128) 7·90 5 0·16
Alive and independent (mRS 0–2), <3 h 90 (46 to 135) 1·87 5 0·87
Alive and independent (mRS 0–2), 3–6 h 18 (–10 to 45)* 9·86 6 0·13
Dead by end of follow-up, <3 h –15 (–55 to 25)* 8·26 6 0·22
Dead by end of follow-up, 3–6 h 18 (–3 to 39)* 10·68 6 0·10
Symptomatic intracranial haemorrhage, <3 h 68 (49 to 87) 3·12 5 0·68
Symptomatic intracranial haemorrhage, 3–6 h 58 (46 to 70) 3·55 6 0·74
Outcome by age and time to treatment
Treatment up to 6 h after stroke
Alive and independent (mRS 0–2), ≤80 years 43 (16 to 70) 19·22 9 0·02
Alive and independent (mRS 0–2), >80 years 38 (–3 to 79) 2·14 2 0·34
Treatment up to 3 h
Alive and independent (mRS 0–2), ≤80 years 95 (35 to 155) 3·64 5 0·60
Alive and independent (mRS 0–2), >80 years 96 (35 to 157) 0·67 1 0·41
Treatment between 3–6 h
Alive and independent (mRS 0–2), ≤80 years 23 (–8 to 54) 8·91 6 0·18
Alive and independent (mRS 0–2), >80 years –5 (–61 to 50) 0 1 0·95
rt-PA=recombinant tissue plasminogen activator. Df=degrees of freedom. mRS=modiﬁ ed Rankin Scale. *A minus 
indicates fewer events per 1000 patients treated with rt-PA.
Table 2: Absolute eﬀ ects of rt-PA per 1000 patients treated and between trial heterogeneity, all outcomes
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subcutaneous heparin was allowed within 24 h of rt-PA 
in three trials;2,3,7 and antithrombotic drugs were not 
allowed until 24 h after rt-PA in the other trials. Data for 
all outcomes were not provided in all trials but all 
available data were used.
The eﬀ ects of rt-PA on the early outcomes are shown in 
ﬁ gure 1 and the absolute event rates per 1000 patients 
treated with estimates of heterogeneity are provided in 
table 2. Data for deaths within 7 days, available from eight 
trials,2,3,7,13,15,19–21 showed that 8·9% of patients allo cated 
rt-PA and 6·4% allocated control died within 7 days 
(ﬁ gure 1), an absolute increase of 25 deaths per 
1000 individuals treated (table 2).
Data for fatal intracranial haemorrhage within 7 days, 
available from eight trials,1–3,7,15–18,21 showed that 3·6% 
of patients allocated rt-PA and 0·6% of those allocated the 
control died from intracranial haemorrhage (ﬁ gure 1), an 
absolute increase of 29 deaths per 1000 patients.
There was no evidence that rt-PA increased the 
number of deaths within 7 days from causes other than 
intra cranial haemorrhage (ﬁ gure 1), implying that the 
excess of early deaths with rt-PA is mostly from fatal 
intracranial haemorrhage, although it should be noted 
that data were only available from ﬁ ve trials.2,3,7,15,21 
Although no between-trial heterogeneity was noted 
(table 2), there was marginal heterogeneity between pre-
vious trials as a group and IST-3 (p=0·04; ﬁ gure 1).
Data for symptomatic intracranial haemorrhage within 
7 days, available from all 12 trials, showed that 7·7% of 
patients allocated rt-PA and 1·8% allocated control 
developed this haemorrhage (ﬁ gure 1; appendix p 5). 
The crude estimate of the absolute excess of symptom-
atic intracranial haemorrhage with rt-PA was 58 per 
1000 patients treated (table 2).
Data for symptomatic infarct swelling within 7 days 
was available from six trials;1–3,7,17,18,21 10·2% allocated rt-PA 
and 10·4% allocated control developed infarct swelling 
(ﬁ gure 1), with substantial between-trial hetero geneity 
(table 2) mostly due to diﬀ erences between IST-3 and 
previous trials (p=0·001 ﬁ gure 1).
The eﬀ ects on outcomes at ﬁ nal follow-up are shown in 
ﬁ gure 2 and the absolute event rates in table 2. Data for 
deaths between 7 days and the end of follow-up, available 
from eight trials,2,3,7,13,15,19–21 showed that 11·5% of patients 
allocated rt-PA and 13·6% allocated control died in this 
period (ﬁ gure 2), a reduction of 22 deaths per 
1000 individuals treated with rt-PA (table 2).
Data for total number of deaths from all causes by the 
end of follow-up, available from all 12 trials, showed that 
19·1% allocated rt-PA and 18·5% allocated control died 
(ﬁ gure 2; appendix p 5), equivalent to a non-signiﬁ cant 
increase in deaths of seven per 1000 patients treated 
with rt-PA.
Data for patients who were alive and indepen-
dent (mRS 0–2) were available from ten trials 
(appen dix p 6).1–3,7,13,16–21 46·3% of patients allocated rt-PA 
and 42·1% allocated control were alive and independent 
(mRS 0–2) at the end of follow-up (ﬁ gure 2), an absolute 
increase of 42 per 1000 people treated with rt-PA 
(table 2).
Figure 2: Eﬀ ects of rt-PA on outcomes at ﬁ nal follow-up
Data are numbers, unless otherwise indicated. Treatment was administered up to 6 h after the stroke. rt-PA=recombinant tissue plasminogen activator. IST-3=Third 
International Stroke Trial. mRS=modiﬁ ed Rankin Scale.
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Data for patients who were alive with favourable 
outcome (mRS 0–1) were available in the same ten trials 
(appendix p 6). 34·8% of patients allocated rt-PA and 
29·3% allocated control had mRS 0–1 at the end of 
follow-up (ﬁ gure 2), equivalent to 55 more patients alive 
and almost symptom free per 1000 treated (table 2). 
Heterogeneity was noted between all trials (table 2) 
but not between previous trials combined and IST-3 
(ﬁ gure 2).
Data for patients treated within 3 h and between 3–6 h 
after stroke were available for three key outcomes 
(ﬁ gure 3, table 2). Among patients treated within 3 h of 
stroke, using a cutoﬀ  of mRS 0–1 (six trials1–3,16,18,21), 
283 (31·6%) of 896 allocated rt-PA and 202 (22·9%) of 
883 allocated control achieved a favourable outcome 
(OR 1·61, 95% CI 1·30–1·99, p<0·0001), an absolute 
increase of 87 per 1000 individuals given rt-PA. Among 
patients treated within 3 h of stroke (six trials1–3,16,18,21), 
40·7% allocated rt-PA and 31·7% allocated control 
achieved mRS 0–2 (ﬁ gure 3), an absolute increase of 
90 per 1000 patients treated (table 2). Of the patients 
treated between 3–6 h after stroke (seven trials2,3,7,16,17,20,21), 
47·5% allocated rt-PA and 45·7% allocated control 
achieved mRS 0–2 (ﬁ gure 2), an absolute increase of 
18 per 1000 patients treated. The diﬀ erence in ORs 
between the subgroups treated within 3 h and between 
3–6 h was signiﬁ cant (χ²=9·49, 2 degrees of freedom (df), 
p=0·002). There were slightly fewer deaths by the end of 
follow-up in people treated within 3 h (seven trials;1–3,15,16,18,21 
ﬁ gure 3), equiva lent to 15 fewer deaths per 1000 (table 2), 
but slightly more deaths in those treated between 3–6 h 
(seven trials;2,3,7,16,17,20,21 ﬁ gure 3), equivalent to an excess of 
18 per 1000 individuals who were treated with rt-PA. 
However, the diﬀ erence in ORs between the subgroups 
treated within 3 h and between 3–6 h was not signiﬁ cant 
(χ²=3·20, df 2, p=0·07). No diﬀ erence was noted in the 
Figure 3: Eﬀ ects of rt-PA on alive and independent (mRS 0–2) and death by the end of follow-up and on symptomatic intracranial haemorrhage within the 
ﬁ rst 7 days, by time to treatment
Data are numbers, unless otherwise indicated. rt-PA=recombinant tissue plasminogen activator. IST-3=Third International Stroke Trial. mRS=modiﬁ ed Rankin Scale.
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summary ORs for symptomatic intracranial haem or-
rhage for those treated within 3 h (six trials;1–3,16,18,21 
ﬁ gure 3), equivalent to 68 more such haemorrhages per 
1000 treated individuals (table 2), and for those treated 
between 3–6 h (seven trials;2,3,7,16,17,20,21 ﬁ gure 3), equivalent 
to 58 more per 1000 treated patients (table 2; test for 
diﬀ erence between subgroups χ²=0·57, df 2, p=0·45). 
The results were the same when the analysis was 
restricted to the trials of treatment in both time windows 
(data not shown). No heterogeneity was noted between 
trials, or between previous trials combined and IST-3, for 
any of the outcomes within 3 h and between 3–6 h.
Three trials included a total of 1711 patients older than 
80 years (25 from EPITHET, 69 from NINDS, the rest 
from IST-3).1,20,21 Among patients older than 80 years who 
were treated within 6 h, 27·2% allocated rt-PA and 23·4% 
allocated control were mRS 0–2 (p=0·07; ﬁ gure 4), an 
increase of 38 per 1000 individuals were alive and 
independent (table 2). Among patients aged 80 years and 
younger, 52·5% allocated rt-PA and 48·3% allocated 
control were alive and independent (mRS 0–2) at the end 
of follow-up (p=0·009), an increase of 43 per 1000 people 
(table 2). For patients older than 80 years treated within 
3 h, 28·9% allocated rt-PA and 19·3% allocated control 
were alive and independent (ﬁ gure 4; p=0·003), an 
increase of 96 per 1000 people (table 2). Among those 
80 years and younger treated within 3 h, 49·6% allocated 
rt-PA and 40·1% allocated control were alive and 
independent (ﬁ gure 4; p=0·001), an increase of 95 per 
1000 people (table 2). Among people treated between 
3–6 h after stroke, of those aged 80 years and younger 
52·6% allocated rt-PA and 50·3% allocated control 
achieved mRS 0–2 at the end of follow-up compared with 
25·9% allocated rt-PA and 26·4% allocated control who 
were older than 80 years (ﬁ gure 4).
Tabular data were too few to provide reliable evidence 
about the eﬀ ects of antithrombotic drugs in addition to 
rt-PA, and were not available to assess the eﬀ ect of 
presence or absence of visible infarction on imaging or 
by baseline stroke severity on main outcomes.
Discussion
The data reported in this systematic review and meta-
analysis for 7012 patients showed that for every 
1000 patients allocated intravenous rt-PA up to 6 h after 
stroke, 42 more patients were alive and independent 
(mRS 0–2); 55 more were alive with a favourable 
outcome (mRS 0–1) at the end of follow-up. This beneﬁ t 
occurred despite an increase in the number of early 
symptomatic intracranial haemorrhages and early 
deaths. These early hazards were oﬀ set by a reduction 
in the number of deaths between 7 days and the end of 
follow-up, and so, by the end of follow-up, no eﬀ ect on 
deaths from all causes was apparent, and the number 
who were dependent (mRS 3–5) was reduced. Earlier 
treatment is better, leading to an increase in the number 
of patients who were alive with favourable outcomes 
(mRS 0–1) and alive and independent (mRS 0–2) with 
treatment within 3 h of stroke. Among the 1711 patients 
older than 80 years, the absolute beneﬁ ts from rt-PA 
were at least as large as for the younger patients, 
especially with early treatment.
Do the eﬀ ects of rt-PA in the 3035 patients in IST-3 
(95% of whom did not meet contemporaneous 
European licence criteria) diﬀ er materially from the 
eﬀ ects in the 3977 patients from 11 previous trials (who 
largely did meet these criteria)? The characteristics of 
patients in IST-3 that excluded them from the licence 
criteria were chieﬂ y age and time: 53% were older than 
80 years, 72% were treated more than 3 h after stroke 
Figure 4: Eﬀ ect of rt-PA on alive and independent at the end of follow-up, subgrouped by age and time to treatment
Data are numbers, unless otherwise indicated. rt-PA=recombinant tissue plasminogen activator. IST-3=Third International Stroke Trial.
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onset. A large proportion had severe strokes and 
146 (5%) had National Institutes of Health Stroke Scale 
greater than 25, hence the fairly high numbers of deaths 
in both the rt-PA and control groups. There was no 
evidence to suggest that any of the beneﬁ cial or adverse 
eﬀ ects of rt-PA were qualitatively diﬀ erent in these 
outside-licence patients from individuals in earlier 
trials, except for non-intracranial-haemorrhage early 
deaths and symptomatic infarct swelling. The propor-
tion of patients with sympto matic infarct swelling in 
IST-3 (3·6%) was less than that of previous trials 
(17·3%) but the results of IST-3 showed an increase in 
symptomatic infarct swelling with rt-PA, whereas those 
of previous trials had suggested a reduction (p=0·06). 
These diﬀ erences could be attrib utable to several 
factors: the analysis of symptomatic oedema and its 
deﬁ nition were prespeciﬁ ed in IST-3 but not in ﬁ ve of 
11 previous trials that provided relevant data; patients in 
IST-3 were older, had more severe strokes (hence larger 
infarcts), and were treated later than in previous trials. 
These and other possibly aggregate characteristics 
could have changed the eﬀ ect of rt-PA on symptomatic 
infarct swelling and in turn the eﬀ ect on non-
intracranial-haemorrhage early deaths; these points 
merit further analysis.
The updated review provides additional insights. First, 
the ﬁ nding that fewer deaths occurred with rt-PA 
between 7 days and late follow-up in IST-3 conﬁ rms a 
pattern suspected in previous trials, and indicates that 
the excess hazard with rt-PA is largely attributable to 
symptomatic intracranial haemorrhage and occurs early, 
so that patients who survive the acute phase without 
intracranial haemorrhage beneﬁ t. One explanation for 
this might be that more dis abled stroke survivors have 
an ongoing higher risk of death;22 rt-PA, by shifting the 
balance towards better functional outcome, reduces the 
risk of death in the long term. The longer follow-up in 
IST-3 (6 months vs 3 months in previous trials), might 
have allowed this net balance of early hazard versus later 
beneﬁ t to emerge more clearly. Second, the beneﬁ ts of 
rt-PA occur in severe and milder strokes. Third, as 
suggested by the results of non-randomised studies,23,24 
the relative and absolute beneﬁ ts of rt-PA are at least as 
large in older as in younger people (ﬁ gure 4, table 2). 
Fourth, the new data reinforce the evidence that beneﬁ t 
is greatest when rt-PA is given within 3 h. Therefore, 
eﬀ orts to reduce treatment delays should continue, 
particularly for older people.
The latest time window for beneﬁ t remains unclear. 
Although beneﬁ t from thrombolysis clearly declines with 
increasing delay to treatment,8 these data suggest that 
beneﬁ t probably extends beyond 4·5 h, possibly as late as 
6 h in some patients, though the time probably varies 
with key individual or combined patients’ charac teristics, 
which were not possible to identify with just summary 
unadjusted data. Patients presenting later are diﬀ erent 
(eg, less severe stroke) than those presenting earlier. The 
lower beneﬁ t with later treatment is not due to more 
symptomatic intracranial haemorrhage because the odds 
of this haemorrhage with rt-PA are actually slightly lower 
in patients treated between 3–6 h than within 3 h 
(ﬁ gure 3, table 2). Thus, non-signiﬁ cantly more deaths 
and the reduction in the OR for alive and independent at 
the end of follow-up for treatment between 3–6 h might 
indicate less beneﬁ t with later treatment—ie, less tissue 
to salvage, rather than simply more hazard.
An analysis of individual patient data from all 12 trials is 
essential to ﬁ nd out the eﬀ ect of rt-PA in patients with 
diﬀ erent severities and subtypes of stroke (particularly 
lacunar stroke), by appearance of the ischaemic lesion 
or rest of the brain on imaging, in key subgroups of 
patients—eg, those in atrial ﬁ brillation, on aspirin 
before stroke, with high blood pressure or diabetes—with 
narrow time windows and functional outcome strata, and 
by diﬀ erent doses of rt-PA, and to deﬁ ne the latest time for 
beneﬁ t. Identifying how to avoid sympto matic intra-
cranial haemorrhage is critical, because it is the single 
largest hazard. Ongoing trials, Thrombolysis in Elderly 
Stroke Patients in Italy (TESPI),25 Enhanced Control 
of Hypertension and Thrombolysis Stroke Study 
(ENCHANTED), or EX tending the time for Thrombolysis 
in Emergency Neurological Deﬁ cits (EXTEND26) are 
addressing treat ment in the elderly or at later times and 
ways to reduce the risk of haemorrhage—eg, whether a 
lower dose of rt-PA or blood pressure lowering can reduce 
symptomatic intracranial haemor rhage. Trials to invest-
igate alternative doses, routes of thrombolytic drug admin-
istration, diﬀ erent thrombolytic drugs, and mechanical 
thromb ectomy and advanced imaging could help identify 
patients for whom these alternative therapies might be 
more eﬀ ective than is intravenous rt-PA. Information 
about the eﬀ ect of thrombolysis on long-term survival free 
of dependence is sparse (with NINDS1 being the only trial 
so far in which outcomes at 12 months have been reported; 
for IST-3 the intention is to report functional outcome up 
to 18 months and overall survival thereafter21) but this 
study will be important for understanding the true health 
economic eﬀ ect of thrombolytic treatment. If small gains 
in functional ability by 3–6 months translate into greater 
long-term survival free of disability,22 this is likely to 
reduce health-care costs and increase quality of life and 
cost-eﬀ ectiveness.
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